Coccidioidomycosis Drug Global Market Report 2025

The coccidioidomycosis drug market size has grown strongly in recent years. It will grow from $0.33 billion in 2024 to $0.36 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth during the historic period can be attributed to the rising incidence of valley fever, increasing awareness of coccidioidomycosis, advancements in antifungal medications, the expansion of healthcare infrastructure in endemic regions, increased government funding for rare disease research, the growing population of immunocompromised patients, and strengthened collaboration between pharmaceutical companies and healthcare providers.

The coccidioidomycosis drug market size is expected to see rapid growth in the next few years. It will grow to $0.48 billion in 2029 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to the rising prevalence of valley fever, a growing population in endemic regions, the expansion of personalized medicine, an increasing number of severe coccidioidomycosis cases, advancements in fungal resistance management, rising healthcare expenditure in endemic areas, ongoing clinical trials for new therapies, improved treatment access in underserved regions, and a greater focus on rare disease management. Key trends expected during this period include advancements in artificial intelligence for drug discovery, the use of machine learning for treatment personalization, the development of targeted antifungal therapies, the integration of genomic data for precision medicine, improved diagnostic tools utilizing molecular biomarkers, the growth of telemedicine for remote patient management, innovations in nanoparticle-based drug delivery, the use of big data for epidemiology and treatment outcomes, advancements in real-time patient monitoring technology, and the development of virtual clinical trial platforms.

The growing number of immunocompromised individuals is expected to drive the expansion of the coccidioidomycosis drug market in the coming years. Immunocompromised individuals have weakened immune systems, making them more vulnerable to infections and illnesses, including those with human immunodeficiency virus (HIV), cancer, or a history of organ transplants. The increase in immunocompromised populations is driven by factors such as the rising prevalence of chronic diseases, higher rates of organ transplants, widespread use of immunosuppressive therapies, and the growing incidence of HIV/AIDS. Coccidioidomycosis drugs play a critical role in helping immunocompromised patients by controlling fungal infections, reducing disease severity, and preventing complications such as disseminated coccidioidomycosis, which can be life-threatening due to weakened immune responses. For instance, in July 2024, the Joint United Nations Programme on HIV/AIDS (UNAIDS), a Switzerland-based United Nations organization, reported that approximately 39.9 million people were living with HIV in 2023, up from 39 million in 2022. As a result, the increasing number of immunocompromised individuals is driving the growth of the coccidioidomycosis drug market.

Leading companies in the coccidioidomycosis drug market are making strategic investments to develop advanced antifungal therapies and improve treatment effectiveness. These investments enable companies to conduct clinical trials exploring novel drug formulations and combination therapies aimed at targeting drug-resistant fungal strains and enhancing patient outcomes. For example, in February 2022, researchers at the University of California, Los Angeles (UCLA), a US-based public research university, launched a center to investigate why some individuals experience severe effects from coccidioidomycosis (valley fever) while others remain unaffected. This joint initiative, involving researchers from UCLA, the University of California, San Diego (UCSD), and the National Institutes of Health (NIH), is funded by an NIH grant and supports four research projects focusing on innate and adaptive immune responses, the genomic basis of coccidioidomycosis, and fungal virulence factors.

In November 2023, Basilea Pharmaceutica Ltd., a Switzerland-based biopharmaceutical company, acquired the rights to fosmanogepix from Amplyx Pharmaceuticals Inc. for an undisclosed amount. This acquisition positions Basilea to initiate its first phase III study with fosmanogepix in 2024, further strengthening its presence in the antifungal treatment market and addressing the urgent need for new antifungal therapies. Amplyx Pharmaceuticals Inc. is a US-based pharmaceutical company and an affiliate of Pfizer Inc., specializing in developing treatments for infectious diseases, including coccidioidomycosis.

Major players in the coccidioidomycosis drug market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Bristol Myers Squibb, Novartis AG, Gilead Sciences Inc., Viatris Inc., Teva Pharmaceuticals USA Inc., Baxter International Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Apotex Inc., Cipla Limited, Dr. Reddy's Laboratories, Zydus Group, Amneal Pharmaceuticals Inc., Recordati S.p.A., Glenmark Pharmaceuticals Limited, Xellia Pharmaceuticals Pvt. Ltd., Brundavan laboratories Pvt. Ltd., LGM Pharma, Enomark Pharma.

North America was the largest region in the coccidioidomycosis drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in coccidioidomycosis drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the coccidioidomycosis drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Coccidioidomycosis drugs are medications designed to treat infections caused by *Coccidioides* species, the fungi responsible for valley fever. These drugs, including azole and polyene antifungals, help control fungal growth and alleviate symptoms. Treatment varies based on infection severity, utilizing oral, intravenous, or long-term therapy, particularly for immunocompromised patients to prevent complications.

The primary drug types in the coccidioidomycosis drug market include azoles, echinocandins, and polyenes. Azoles are a class of antifungal drugs that inhibit the synthesis of ergosterol, a crucial component of fungal cell membranes. Treatment is administered through oral or intravenous routes, with distinct phases including the acute phase, chronic phase, and prophylactic treatment. Patients are categorized into immunocompetent and immunocompromised groups, while end-users include specialty clinics, hospitals, homecare, and others.

The coccidioidomycosis drug market research report is one of a series of new reports that provides coccidioidomycosis drug market statistics, including coccidioidomycosis drug industry global market size, regional shares, competitors with a coccidioidomycosis drug market share, detailed coccidioidomycosis drug market segments, market trends and opportunities, and any further data you may need to thrive in the coccidioidomycosis drug industry. This coccidioidomycosis drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The coccidioidomycosis drug market consists of revenues earned by entities by providing services such as diagnostic testing, patient management programs, pharmacovigilance services, drug consultation and advisory, clinical trials for new treatments, and education and awareness campaigns aimed at improving diagnosis, treatment adherence and overall patient outcomes. The market value includes the value of related goods sold by the service provider or included within the service offering. The coccidioidomycosis drug market also includes sales of antifungal medications and other treatment options, along with diagnostic kits, treatment formulations, intravenous therapies, and combination drug therapies designed to manage and treat valley fever and related complications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.